

✓ -- THERAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM (CD40L)  
MONOCLONAL ANTIBODY 5C8 IN THE TREATMENT OF  
VASCULITIS --

IN THE ABSTRACT\*

Please replace the Abstract with the following:

C1 -- Activation of cells bearing CD40 on their surface by  
CD40 ligand is inhibited by contacting the cells with an agent  
capable of inhibiting interaction between CD40 ligand and the  
cells, in an amount effective to inhibit activation of the cells.  
Activation of cells bearing CD40 on their surface by CD40 ligand  
in a subject is inhibited by administering to the subject an  
agent capable of inhibiting the interaction between CD40 ligand  
and the cells, in an amount effective to inhibit activation of  
the cells. Conditions dependent on CD40 ligand-induced  
activation of CD40-bearing cells are treated, in particular  
vasculitis. --

IN THE CLAIMS\*

✓ Please cancel claims 1 and 102 to 144, without  
prejudice.

Please add claims 145 to 166 as follows:

C2 145. (added) A method for treating vasculitis in a human,  
other than a transplant recipient, comprising the step of  
administering to said human an antibody, Fab, F(ab)'2 or a single  
chain antibody, which binds specifically to an antigen  
specifically bound by monoclonal antibody 5c8, produced by the  
hybridoma having ATCC Accession No. HB 10916, wherein said

---

\*The amendments to the Title and Abstract, are indicated  
in the Appendix hereto (Exhibit A) for the Examiner's  
convenience. The added claims are also set forth in the  
Appendix.